These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 23238745)

  • 41. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor.
    Montuori N; Salzano S; Rossi G; Ragno P
    FEBS Lett; 2000 Jul; 476(3):166-70. PubMed ID: 10913606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urokinase activates calcium-dependent potassium channels in U937 cells via calcium release from intracellular stores.
    Christow SP; Bychkov R; Schroeder C; Dietz R; Haller H; Dumler I; Gulba DC
    Eur J Biochem; 1999 Oct; 265(1):264-72. PubMed ID: 10491182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
    Huang S; New L; Pan Z; Han J; Nemerow GR
    J Biol Chem; 2000 Apr; 275(16):12266-72. PubMed ID: 10766865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.
    Alfano M; Mariani SA; Elia C; Pardi R; Blasi F; Poli G
    Blood; 2009 Feb; 113(8):1699-709. PubMed ID: 18941116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.
    Larusch GA; Merkulova A; Mahdi F; Shariat-Madar Z; Sitrin RG; Cines DB; Schmaier AH
    Am J Physiol Heart Circ Physiol; 2013 Aug; 305(3):H305-20. PubMed ID: 23709605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
    Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
    J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
    Carriero MV; Stoppelli MP
    Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The urokinase receptor interactome.
    Eden G; Archinti M; Furlan F; Murphy R; Degryse B
    Curr Pharm Des; 2011; 17(19):1874-89. PubMed ID: 21711237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. uPA-uPAR molecular complex is involved in cell signaling during neuronal migration and neuritogenesis.
    Lino N; Fiore L; Rapacioli M; Teruel L; Flores V; Scicolone G; Sánchez V
    Dev Dyn; 2014 May; 243(5):676-89. PubMed ID: 24481918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
    Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
    Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
    Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
    J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
    Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
    Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway.
    Cheng X; Shen Z; Yin L; Lu SH; Cui Y
    J Biol Chem; 2009 Nov; 284(45):30897-906. PubMed ID: 19717562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The cleavage of the urokinase receptor regulates its multiple functions.
    Montuori N; Carriero MV; Salzano S; Rossi G; Ragno P
    J Biol Chem; 2002 Dec; 277(49):46932-9. PubMed ID: 12297505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aggregated low-density lipoprotein induce impairment of the cytoskeleton dynamics through urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor in human vascular smooth muscle cell.
    Lugano R; Peña E; Badimon L; Padró T
    J Thromb Haemost; 2012 Oct; 10(10):2158-67. PubMed ID: 22906080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
    Ahmed N; Oliva K; Wang Y; Quinn M; Rice G
    Br J Cancer; 2003 Jul; 89(2):374-84. PubMed ID: 12865932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Degradation of internalized αvβ5 integrin is controlled by uPAR bound uPA: effect on β1 integrin activity and α-SMA stress fiber assembly.
    Wang L; Pedroja BS; Meyers EE; Garcia AL; Twining SS; Bernstein AM
    PLoS One; 2012; 7(3):e33915. PubMed ID: 22470492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
    Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
    Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels.
    Alfano D; Iaccarino I; Stoppelli MP
    J Biol Chem; 2006 Jun; 281(26):17758-67. PubMed ID: 16632475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.